The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study
Open accessAbstract
BACKGROUND: The clinical course of advanced adrenocortical carcinoma (ACC) is heterogeneous. Our study aimed primarily to refine and make headway in the prognostic stratification of advanced ACC. PATIENTS AND METHODS: Patients with advanced ENSAT ACC (stage III or stage IV) at diagnosis registered between 2000 and 2009 in the ENSAT database were enrolled. The primary end point was overall survival (OS). Parameters of potential prognostic relevance were selected. Univariate and multivariate analyses were carried out: model 1 'before surgery'; model 2 'post-surgery'. RESULTS: Four hundred and forty-four patients with advanced ENSAT ACC (stage III: 210; stage IV: 234) were analyzed. After a median follow-up of 55.2 months, the median OS was 24 months. A modified ENSAT (mENSAT) classification was validated: stage III (invasion of surrounding tissues/organs or the vena renalis/cava) and stage IVa, IVb, IVc (2, 3 or >3 metastatic organs, including N, respectively). Two- or 5-year OS was 73%, 46%, 26% and 15% or 50%, 15%, 14% and 2% for stages III, IVa, IVb and IVc, respectively. In the multivariate analysis, mENSAT stages (stages IVa, IVb, or IVc, respectively) were significantly correlated with OS (P < 0.0001), as well as additional parameters: age ≥ 50 years (P < 0.0001), tumor- or hormone-related symptoms (P = 0.01 and 0.03, respectively) in model 1 but also the R status (P = 0.001) and Grade (Weiss >6 and/or Ki67 ≥ 20%, P = 0.06) in model 2. CONCLUSION: The mENSAT classification and GRAS parameters (Grade, R status, Age and Symptoms) were found to best stratify the prognosis of patients with advanced ACC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic characterization of adrenocortical carcinoma
Assié, G., Letouzé, E., Fassnacht, M., Jouinot, A., Luscap, W., Barreau, O., Omeiri, H., Rodriguez, S., Perlemoine, K., René-Corail, F., et al. (2014) · Nature Genetics · doi:10.1038/ng.2953 · Cited by 732
Self-citationFassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Self-citationIcard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Golden, S. H., Robinson, K. A., Saldanha, I., Anton, B., & Ladenson, P. W. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2291 · Cited by 542
Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors
Bilimoria, K. Y., Shen, W. T., Elaraj, D., Bentrem, D. J., Winchester, D. J., Kebebew, E., & Sturgeon, C. (2008) · Cancer · doi:10.1002/cncr.23886 · Cited by 493
Abiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2730 · Cited by 435
Self-citationSchulick, R. D., & Brennan, M. F. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0719-7 · Cited by 366 · cited 1×
“Historically, the prognosis of ACC was shown to be mainly driven by the presence of metastases and tumor resecability [6].”
BackgroundKerkhofs, T. M. A., Verhoeven, R. H. A., Van der Zwan, J. M., Dieleman, J., Kerstens, M. N., Links, T. P., Van de Poll-Franse, L. V., & Haak, H. R. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.034 · Cited by 341
Self-citationAdrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Berruti, A., Baudin, E., Gelderblom, H., Haak, H. R., Porpiglia, F., Fassnacht, M., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds231 · Cited by 331
Self-citationAdrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization
Stojadinovic, A., Ghossein, R. A., Hoos, A., Nissan, A., Marshall, D., Dudas, M. E., Cordon‐Cardo, C., Jaques, D. P., & Brennan, M. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.941 · Cited by 312
Cited by
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Self-citationUpdate on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours
Lam, A. K.-Y. (2017) · Endocrine Pathology · doi:10.1007/s12022-017-9484-5 · Cited by 462
Fassnacht, M., Assie, G., Baudin, E., Eisenhofer, G., de la Fouchardiere, C., Haak, H. R., de Krijger, R., Porpiglia, F., Terzolo, M., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2099 · Cited by 436
Self-citationValidation of the prognostic role of the “Helsinki Score” in 225 cases of adrenocortical carcinoma
Duregon, E., Cappellesso, R., Maffeis, V., Zaggia, B., Ventura, L., Berruti, A., Terzolo, M., Fassina, A., Volante, M., & Papotti, M. (2017) · Human Pathology · doi:10.1016/j.humpath.2016.09.035 · Cited by 98
“Beyond its diagnostic role, the Weiss Score also possesses prognostic significance [7], because high Weiss Score tumors generally display an aggressive clinical behavior [8], although this finding was not confirmed in other papers [17,18].”
ResultSelf-citationUrine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma
Chortis, V., Bancos, I., Nijman, T., Gilligan, L. C., Taylor, A. E., Ronchi, C. L., O’Reilly, M. W., Schreiner, J., Asia, M., Riester, A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz141 · Cited by 93
Self-citation
Metadata
- Authors
- Libé, R., Borget, I., Ronchi, C. L., Zaggia, B., Kroiss, M., Kerkhofs, T., Bertherat, J., Volante, M., Quinkler, M., Chabre, O., Bala, M., Tabarin, A., Beuschlein, F., Vezzosi, D., Deutschbein, T., Borson-Chazot, F., Hermsen, I., Stell, A., Fottner, C., Leboulleux, S., Hahner, S., Mannelli, M., Berruti, A., Haak, H., Terzolo, M., Fassnacht, M., & Baudin, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 26
- Issue
- 10
- Pages
- 2119-2125
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2175623323
- Cited by
- 263
- References
- 18
- FWCI
- 16.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. https://app.cochat.ai/papers/10.1093/annonc/mdv329
- The paper
- Libé, R., Borget, I., Ronchi, C. L., Zaggia, B., Kroiss, M., Kerkhofs, T., Bertherat, J., Volante, M., Quinkler, M., Chabre, O., Bala, M., Tabarin, A., Beuschlein, F., Vezzosi, D., Deutschbein, T., Borson-Chazot, F., Hermsen, I., Stell, A., Fottner, C., . . . Baudin, E. (2015). Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Annals of Oncology. https://doi.org/10.1093/annonc/mdv329
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.